logo
Questions? +1 (202) 335-3939 Login
Set Up FREE Account Submit Release
Trusted News Since 1995
A service for medical industry professionals · Tuesday, July 15, 2025 · 830,542,410 Articles · 3+ Million Readers
Home  •••  Newswires by Industry  •  Countries  •  U.S. States  •  World Media Directory
Prostate Cancer News  •••  Topics  •  Countries  •  U.S. States

Prostate Cancer Options News Monitoring

  • Published on 07:53 GMT

    Do I have prostate cancer? Why a simple PSA blood test alone won’t give you the answer

    Prostate cancer is the most common cancer in Australia, with about 26,000 men diagnosed per year. The majority (more than 85%) are aged over 60. Prostate cancer kills around 3,900 Australians a year. Yet most prostate cancers progress very slowly and many …

    Source: The Conversation - Neutral
  • Published on 08:10 GMT

    Leaks do not have to limit life: Treating and managing urinary incontinence

    Urinary incontinence affects millions across the world, yet it remains one of the most misunderstood and under-discussed medical conditions. For many, it is not just a health issue, but a concern that impacts dignity, confidence, and everyday life. It is …

    Source: The Hindu - Center-left
  • Published on Jul 11, 2025

    Prostate Cancer and Importance of Early Screening

    Bengaluru: Prostate cancer remains one of the most frequently diagnosed malignancies among men worldwide, including in India. Despite its growing incidence, awareness around timely detection remains low. Many individuals seek consultation only after …

    Source: The Hans India - Neutral
  • Published on Jul 11, 2025

    Size Matters In Prostate Cancer

    KUALA LUMPUR, July 11 — For men, an enlarged prostate can be one of the earliest signs that something is amiss. However, an enlarged prostate and other symptoms such as difficulty urinating are often dismissed as normal signs of ageing. Ignoring these …

    Source: CodeBlue - Neutral
  • Published on Jul 11, 2025

    EMBARK Trial Shows Xtandi Combination Demonstrates Significant Overall Response in Non-Metastatic Hormone-Sensitive ...

    Key Takeaways Xtandi plus leuprolide significantly improves overall survival: In patients with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence, the combination reduced the risk of metastasis or death by 58% …

    Source: Applied Clinical Trials - Pending
  • Published on Jul 10, 2025

    Erleada May Be a New Standard of Care for Some With Prostate Cancer

    Recent real-world data suggest that Erleada (apalutamide) may offer an advantage over other treatment options for patients with metastatic castration-sensitive prostate cancer, according to Dr. Mehmet Bilen, a board-certified medical oncologist and lead …

    Source: Cure Today - Neutral
  • Published on Jul 10, 2025

    How Survivorship Differs for Men With Metastatic Prostate Cancer

    The word ‘cure’ and the aspects or survivorship are different for someone living with metastatic prostate cancer compared with those who don’t have metastatic disease, according to Bob Lane, a prostate cancer survivor and patient receiving Erleada ( …

    Source: Cure Today - Neutral
  • Published on Jul 10, 2025

    'A sad loss': Why this prostate cancer treatment is 'disappearing' in NZ

    LDR brachytherapy delivered highly targeted radiation directly to prostate cancer cells, minimising damage to surrounding healthy tissue. Tiny radioactive seeds, each smaller than a grain of rice, were implanted into or near the prostate gland. The seeds …

    Source: Hawke's Bay Today - Neutral
  • Published on Jul 10, 2025

    High-intensity ultrasound emerges as prostate cancer treatment

    Prostate cancer remains one of the most common cancers among men, with the American Cancer Society estimating nearly 300,000 new cases in the U.S. this year alone. While surgery and radiation have long been the standard treatments, a less invasive approach …

    Source: Vero News - Pending
  • Published on Jul 10, 2025

    For advanced prostate cancer, this drug offers hope. Also risks

    A UBC student’s research could help doctors use the promising but costly new medicine. A University of British Columbia student was recognized at the largest cancer conference in North America for her recent work identifying potential side effects of a …

    Source: Bowen Island Undercurrent - Pending
  • Published on Jul 10, 2025

    FDA Grants Breakthrough Device Designation for Artera's AI-Powered Software for Prostate Cancer Care

    July 9, 2025 — Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to ArteraAI …

    Source: Imaging Technology News - New Jersey - Neutral
  • Published on Jul 9, 2025

    Why Some Prostate Tumors Are Resistant to Treatment

    Register for free to listen to this article Thank you. Listen to this article using the player above. ✖ Want to listen to this article for FREE? Complete the form below to unlock access to ALL audio articles. A study from the University of Michigan Rogel …

    Source: Technology Networks - Neutral
  • Published on Jul 9, 2025

    Study identifies why some prostate cancers fail to respond to treatment

    A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment. Treatments such as enzalutamide, which is an androgen …

    Source: Medical News - Neutral
  • Published on Jul 9, 2025

    Pluvicto enters clinical use in Korea amid growing interest in radioligand therapy for prostate cancer

    Novartis' Pluvicto, a next-generation radioligand therapy for metastatic castration-resistant prostate cancer (mCRPC), has begun clinical use in Korea following regulatory approval, offering new hope to patients with limited treatment options. Although …

    Source: Korea Biomedical Review - Neutral
  • Published on Jul 8, 2025

    Study sheds light on why some prostate tumors are resistant to treatment

    ANN ARBOR, Michigan — A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.   Treatments such as enzalutamide, …

    Source: EurekAlert! - Neutral
  • Published on Jul 10, 2025

    FDA-Approved Denosumab Biosimilars Expand Oncology Options in US

    Celltrion USA has announced the US commercial launch of denosumab-bmwo (Stoboclo) and denosumab-bmwo (Osenvelt), biosimilars referencing denosumab (Prolia and Xgeva). These 2 products are among the first wave of denosumab biosimilars to enter the US market …

    Source: Targeted Oncology - Pending
  • Published on Jul 11, 2025

    Spotlight on Shane

    PHOTO BY RUBY F. MCALLISTER PHOTO BY RUBY F. MCALLISTER PHOTO BY RUBY F. MCALLISTER PHOTO BY RUBY F. MCALLISTER PHOTO BY RUBY F. MCALLISTER In addition to the gardens that surround their home on Reinbeck’s West Street, Shane and Kathy Hawkins also maintain …

    Source: Sun Courier - Iowa - Pending
  • Published on Jul 11, 2025

    Community serves up generosity at Langley hospice fundraiser

    Langley Township firefighters crashed the party, but they were most welcome at the annual Plates and Glasses on the Farm fundraising picnic for the Langley Hospice Society. The Saturday, July 5 event came with a surprise visit from representatives of the  …

    Source: Langley Advance Times - Pending
  • Published on Jul 10, 2025

    Denosumab Biosimilars Available in the US for Bone Mets, Multiple Myeloma

    Two indications of denosumab-bmwo (CT-P41; Stoboclo, Osenvelt), referencing 2 other denosumab indications (Prolia, Xgeva), have become commercially available in the US as a treatment for select patients with osteoporosis, multiple myeloma, and solid tumors …

    Source: Cancer Network - New Jersey - Pending

  • 0
  • 0
  • 5
  • 5
days
  • 1
  • 1
  • 9
  • 9
hours
:
  • 3
  • 3
  • 6
  • 6
minutes
:
  • 0
  • 0
  • 4
  • 4
seconds

Featured Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.
Load more prostate cancer news or search news using your own keywords. There are 830,542,410 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Prostate Cancer News by Country >
Prostate Cancer News by U.S. State >
Prostate Cancer News Topics >
Online News Publications >
World News Report >

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter >
Create RSS Feed >
NewsPlugin for WordPress >

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire >
Events >

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 06/17/2025

World Media Directory >

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All
Got news to share? Submit it now.

Healthcare & Pharmaceuticals Events

See All

No event was found.

Become a Member - Join Today!
Join thousands of professionals. Stay current. Stay competitive.
  • Track news from thousands of sources
  • Submit news sources for inclusion in our news tracking algorithm
  • Build your own customized email newsletters
  • Use of our RSS Feeds
  • Includes a complimentary EIN Presswire account plus 1-free release
  • Uncluttered & advertising free news pages

Prostate Cancer News Today by EIN Newsdesk & EIN Presswire (a press release distribution service)

Follow us on Facebook and connect with us on LinkedIn

Newsmatics Inc., 1025 Connecticut Avenue NW, Suite 1000, Washington, DC 20036 · Contact · About

© 1995-2025 Newsmatics Inc., a publisher of EIN News · All Rights Reserved · Privacy Policy · User Agreement